Proteome analysis of serum from type 2 diabetics with nephropathy

Journal of Proteome Research

Volumn 6, Issue 2, 2007, Pages 735-743

  Kim, Hyun Jung ^a   Cho, Eun Hee ^a   Yoo, Ji Hye ^a   Kim, Pan Kyeom ^a   Shin, Jun Seop ^a   Kim, Mi Ryung ^a   Kim, Chan Wha ^a  

^a Korea University   (South Korea)

Author keywords

2 DE; ApoE; Diabetic nephropathy; eGPx; ESI Q TOF MS MS; Serum

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; EXTRACELLULAR GLUTATHIONE PEROXIDASE; GLUTATHIONE PEROXIDASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

BLOOD PROTEINS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GLUTATHIONE PEROXIDASE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PROTEOME; PROTEOMICS;

EID: 33847395363     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr060489g     Document Type: Article

References (52)

1. Yung, S.; Lee, C. Y.; Zhang, Q.; Lau, S. K.; Tsang, R. C.; Chan, T. M. Elevated glucose induction of thrombospondin-1 up-regulates fibronectin synthesis in proximal renal tubular epithelial cells through TGF-beta1 dependent and TGF-beta1 independent pathways. Nephrol., Dial., Transplant. 2006, 21 (6), 1504-1513.
2. Krolewski, A. S.; Warram, J. H. Genetic susceptibility to diabetic kidney disease: an update. J. Diabetes Complications 1995, 9 (4), 277-2781.
3. Barnett, A. Prevention of loss of renal function over time in patients with diabetic nephropathy. Am. J. Med. 2006, 119 (5 Suppl 1), S40-47.
4. Wolf, G.; Ritz, E. Diabetic nephropathy in type 2 diabetes prevention and patient management. J. Am. Soc. Nephrol. 2003, 14 (5), 1396-1405.
5. Bennett, P. H.; Haffner, S.; Kasiske, B. L.; Keane, W. F.; Mogensen, C. E.; Parving, H. H.; Steffes, M. W.; Striker, G. E. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific, Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am. J. Kidney Dis. 1995, 25 (1), 107-112.
6. Parving, H. H.; Lehnert, H.; Brochner-Mortensen, J.; Gomis, R.; Andersen, S.; Arner, P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001, 345 (12), 870-878.
7. Mogensen, C. E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N. Engl. J. Med. 1984, 310 (6), 356-360.
8. Nelson, R. G.; Knowler, W. C.; Pettitt, D. J.; Saad, M. F.; Charles, M. A.; Bennett, P. H. Assessment of risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimens. Arch. Intern. Med. 1991, 151 (9), 1761-1765.
9. Brenner, B. M.; Cooper, M. E.; de Zeeuw, D.; Keane, W. F.; Mitch, W. E.; Parving, H. H.; Remuzzi, G.; Snapinn, S. M.; Zhang, Z.; Shahinfar, S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001, 345 (12), 861-869.
10. Lewis, E. J.; Hunsicker, L. G.; Clarke, W. R.; Berl, T.; Pohl, M. A.; Lewis, J. B.; Ritz, E.; Atkins, R. C.; Rohde, R.; Raz, I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001, 345 (12), 851-860.
11. Nelson, R. G.; Newman, J. M.; Knowler, W. C.; Sievers, M. L.; Kunzelman, C. L.; Pettitt, D. J.; Moffett, C. D.; Teutsch, S. M.; Bennett, P. H. Incidence of end-stage renal disease in type 2 (non-insulin-dependent) diabetes mellitus in Pima, Indians. Diabetologia 1988, 31 (10), 730-756.
12. Eurich, D. T.; Majumdar, S. R.; Tsuyuki, R. T.; Johnson, J. A. Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diabetes Care 2004, 27 (6), 1330-1334.
13. Parving, H. H.; Mauer, M.; Ritz, E. Diabetic nephropathy. In The kidney, 7th ed.; Brenner, B. M., Ed.; Saunders: Philadelphia, PA, 2004; Vol. 2, pp 1777-1818.
14. Adler, A. I.; Stevens, R. J.; Manley, S. E.; Bilous, R. W.; Cull, C. A.; Holman, R. R. Development and progression of nephropathy in type 2 diabetes: the United, Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003, 63 (1), 225-232.
15. Dinneen, S. F.; Gerstein, H. C. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch. Intern. Med. 1997, 157 (13), 1413-1418.
16. Gerstein, H. C.; Mann, J. F.; Yi, Q.; Zinman, B.; Dinneen, S. F.; Hoogwerf, B.; Halle, J. P.; Young, J.; Rashkow, A.; Joyce, C.; Nawaz, S.; Yusuf, S. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA, J. Am. Med. Assoc. 2001, 286 (4), 421-426.
17. Garg, J. P.; Bakris, G. L. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc. Med. 2002, 7 (1), 35-43.
18. Merchant, M. L.; Klein, J. B. Proteomics and diabetic nephropathy. Curr. Diabetes Rep. 2005, 5 (6), 464-469.
19. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
20. Joo, W. A.; Kang, M. J.; Son, W. K.; Lee, H. J.; Lee, D. Y.; Lee, E.; Kim, C. W. Monitoring protein expression by proteomics: human plasma exposed to benzene. Proteomics 2003, 3 (12), 2402-2411.
21. Son, W. K.; Lee, D. Y.; Lee, S. H.; Joo, W. A.; Kim, C. W. Analysis of proteins expressed in rat plasma exposed to dioxin using 2-dimensional gel electrophoresis. Proteomics 2003, 3 (12), 2393-2401.
22. Shevchenko, A.; Chernushevich, I.; Ens, W.; Standing, K. G.; Thomson, B.; Wilm, M.; Mann, M. Rapid 'de novo' peptide sequencing by a combination of nanoelectrospray, isotopic labeling and a quadrupole/time-of-flight mass spectrometer. Rapid Commun. Mass Spectrom. 1997, 11 (9), 1015-1024.
23. Bologa, R. M.; Levine, D. M.; Parker, T. S.; Cheigh, J. S.; Serur, D.; Stenzel, K. H.; Rubin, A. L. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am. J. Kidney Dis. 1998, 32 (1), 107-114.
24. Iseki, K.; Fukiyama, K. Predictors of stroke in patients receiving chronic hemodialysis. Kidney Int. 1996, 50 (5), 1672-1675.
25. Takebe, G.; Yarimizu, J.; Saito, Y.; Hayashi, T.; Nakamura, H.; Yodoi, J.; Nagasawa, S.; Takahashi, K. A comparative study on the hydroperoxide and thiol specificity of the glutathione peroxidase family and selenoprotein P. J. Biol. Chem. 2002, 277 (43), 41254-41258.
26. Maddipati, K. R.; Marnett, L. J. Characterization, of the major hydroperoxide-reducing activity of human plasma. Purification and properties of a selenium-dependent glutathione peroxidase. J. Biol. Chem. 1987, 262 (36), 17398-17403.
27. Yoshimura, S.; Suemizu, H.; Taniguchi, Y.; Arimori, K.; Kawabe, N.; Moriuchi, T. The human plasma glutathione peroxidase-encoding gene: organization, sequence and localization to chromosome 5q32. Gene 1994, 145 (2), 293-297.
28. Avissar, N.; Ornt, D. B.; Yagil, Y.; Horowitz, S.; Watkins, R. H.; Kerl, E. A.; Takahashi, K.; Palmer, I. S.; Cohen, H. J. Human kidney proximal tubules are the main source of plasma glutathione peroxidase. Am. J. Physiol. 1994, 266 (2 Pt 1), C367-375.
29. Chu, F. F.; Esworthy, R. S.; Doroshow, J. H.; Doan, K.; Liu, X. F. Expression of plasma glutathione peroxidase in human liver in addition to kidney, heart, lung, and breast in humans and rodents. Blood 1992, 79 (12), 3233-3238.
30. Ozden, M.; Maral, H.; Akaydin, D.; Cetinalp, P.; Kalender, B. Erythrocyte, glutathione peroxidase activity, plasma malondialdehyde and erythrocyte glutathione levels in hemodialysis and CAPD patients. Clin. Biochem. 2002, 35 (4), 269-273.
31. Mimic-Oka, J.; Simic, T.; Djukanovic, L.; Reljic, Z.; Davicevic, Z. Alteration, in plasma antioxidant capacity in various degrees of chronic renal failure. Clin. Nephrol. 1999, 51 (4), 233-241.
32. Ceballos-Picot, I.; Witko-Sarsat, V.; Merad-Boudia, M.; Nguyen, A. T.; Thevenin, M.; Jaudon, M. C.; Zingraff, J.; Verger, C.; Jungers, P.; Descamps-Latscha, B. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radical Biol. Med. 1996, 21 (6), 845-853.
33. Sommerburg, O.; Grune, T.; Ehrich, J. H.; Siems, W. G. Adaptation of glutathion-peroxidase activity to oxidative stress occurs in children but not in adult patients with end-stage renal failure undergoing hemodialysis. Clin. Nephrol. 2002, 58 (Suppl. 1), S31-36.
34. Yamamoto, Y.; Takekoshi, Y.; Itami, N.; Honjo, T.; Kojima, H.; Yano, S.; Takahashi, H.; Saito, I.; Takahashi, K. Enzyme-linked immunosorbent assay for extracellular glutathione peroxidase in serum of normal individuals and patients with renal failure on hemodialysis. Clin. Chim. Acta 1995, 236 (1), 93-99.
35. Yoshimura, S.; Suemizu, H.; Nomoto, Y.; Sakai, H.; Katsuoka, Y.; Kawamura, N.; Moriuchi, T. Plasma glutathione peroxidase deficiency caused by renal dysfunction. Nephron 1996, 73 (2), 207-211.
36. Roxborough, H. E.; Mercer, C.; McMaster, D.; Maxwell, A. P.; Young, I. S. Plasma glutathione peroxidase activity is reduced in haemodialysis patients. Nephron 1999, 81 (3), 278-283.
37. Diamond, J. R.; Karnovsky, M. J. Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation. Kidney Int. 1987, 32 (5), 671-677.
38. Mulec, H.; Johnson, S. A.; Bjorck, S. Relation between serum cholesterol and diabetic nephropathy. Lancet 1990, 335 (8704), 1537-1538.
39. Curtiss, L. K.; Boisvert, W. A. Apolipoprotein E and atherosclerosis. Curr. Opin. Lipidol. 2000, 11 (3), 243-251.
40. Nakashima, Y.; Plump, A. S.; Raines, E. W.; Breslow, J. L.; Ross, R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 1994, 14 (1), 133-140.
41. Park, L.; Raman, K. G.; Lee, K. J.; Lu, Y.; Ferran, L. J., Jr.; Chow, W. S.; Stern, D.; Schmidt, A. M. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 1998, 4 (9), 1025-1031.
42. Lassila, M.; Seah, K. K.; Allen, T. J.; Thallas, V.; Thomas, M. C.; Candido, R.; Burns, W. C.; Forbes, J. M.; Calkin, A. C.; Cooper, M. E.; Jandeleit-Dahm, K. A. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J. Am. Soc. Nephrol. 2004, 15 (8), 2125-2138.
43. Joss, N.; Jardine, A.; Gaffney, D.; Boulton-Jones, J. M. Influence of apolipoprotein E genotype on progression of diabetic nephropathy. Nephron Exp. Nephrol. 2005, 101 (4), e127-133.
44. Chen, G.; Paka, L.; Kako, Y.; Singhal, P.; Duan, W.; Pillarisetti, S. A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion. J. Biol. Chem. 2001, 276 (52), 49142-29147.
45. Bruschi, M.; Catarsi, P.; Candiano, G.; Rastaldi, M. P.; Musante, L.; Scolari, F.; Artero, M.; Carraro, M.; Carrea, A.; Caridi, G.; Zennaro, C.; Sanna-Cherchi, S.; Viola, F. B.; Ferrario, F.; Perfumo, F.; Ghiggeri, G. M. Apolipoprotein, E in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Kidney Int. 2003, 63 (2), 686-695.
46. Houenou, L. J.; D'Costa, A. P.; Li, L.; Turgeon, V. L.; Enyadike, C.; Alberdi, E.; Becerra, S. P. Pigment epithelium-derived factor promotes the survival and differentiation of developing spinal motor neurons. J. Comp. Neurol. 1999, 412 (3), 506-514.
47. Araki, T.; Taniwaki, T.; Becerra, S. P.; Chader, G. J.; Schwartz, J. P. Pigment, epithelium-derived factor (PEDF) differentially protects immature but not mature cerebellar granule cells against apoptotic cell death. J. Neurosci. Res. 1998, 53 (1), 7-15.
48. Aymerich, M. S.; Alberdi, E. M.; Martinez, A.; Becerra, S. P. Evidence for pigment epithelium-derived factor receptors in the neural retina. Invest. Ophthalmol. Visual Sci. 2001, 42 (13), 3287-3293.
49. Liu, H.; Ren, J. G.; Cooper, W. L.; Hawkins, C. E.; Cowan, M. R.; Tong, P. Y. Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc. Natl. Acad. Sci. U.S.A. 2004, 101 (17), 6605-6610.
50. Filleur, S.; Volz, K.; Nelius, T.; Mirochnik, Y.; Huang, H.; Zaichuk, T. A.; Aymerich, M. S.; Becerra, S. P.; Yap, R.; Veliceasa, D.; Shroff, E. H.; Volpert, O. V. Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res. 2005, 65 (12), 5144-5152.
51. Bilak, M. M.; Becerra, S. P.; Vincent, A. M.; Moss, B. H.; Aymerich, M. S.; Kuncl, R. W. Identification, of the neuroprotective molecular region of pigment epithelium-derived factor and its binding sites on motor neurons. J. Neurosci. 2002, 22 (21), 9378-9386.
52. Motomiya, Y; Yamagishi, S; Adachi, H; Abe, A. Increased serum concentrations of pigment epithelium-derived factor in patients with end-stage renal disease. Clin. Chem. 2006, 52 (10), 1970-1971.